Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.54 USD | +3.65% | +16.79% | -29.37% |
11/04 | North American Morning Briefing : Stock Futures -2- | DJ |
10/04 | KeyBanc Downgrades Health Catalyst to Sector Weight From Overweight on Potential Risks to Hospital End Markets | MT |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The company appears to be poorly valued given its net asset value.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- Low profitability weakens the company.
- One of the major weak points of the company is its financial situation.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Software
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-29.37% | 373M | C | ||
-20.12% | 210B | B | ||
-9.13% | 64.99B | B- | ||
-6.30% | 55.1B | B | ||
-13.77% | 45.07B | A- | ||
+3.36% | 42.25B | C | ||
-6.07% | 34.27B | B | ||
-13.32% | 28.07B | B | ||
+81.86% | 22.97B | - | ||
-2.49% | 20.92B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- HCAT Stock
- Ratings Health Catalyst, Inc.